Novo Nordisk’s semaglutide franchise has taken off in a big way. Type 2 diabetes med Ozempic smashed the blockbuster barrier in 2019, the same year the company launched its oral option, Rybelsus. Now, the Danish diabetes major is touting data on a higher-dose prospect. In a late-stage trial, Ozempic 2 mg trumped its 1-mg predecessor on blood… Read More »
The COVID-19 pandemic derailed plans for companies worldwide last year, but Eli Lilly adapted by developing medicines against the novel coronavirus—to the tune of $ 871 million in antibody revenue for Q4—while still pushing sales of its newer meds. Now, CEO David Ricks is reaping the rewards with a pay package that could place him… Read More »
AstraZeneca put the rest of the SGLT2 inhibitor class on notice when its Farxiga scored an FDA heart failure nod in patients with or without diabetes. One of its competitors, Eli Lilly and Boehringer Ingelheim’s Jardiance, is fast on Farxiga’s heels, though, and it’s ready to bring its pivotal trial win in front of physicians. Jardiance, added… Read More »
Sales of Eli Lilly’s migraine and cluster headache med Emgality have lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deploying a full-court press with some new patient data. Just 5% of frequent migraine sufferers who seek emergency care for their symptoms are treated… Read More »
Back in May, new Gilead Sciences CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick. Thursday, the Big Biotech said it would bring on Eli Lilly executive Christi Shaw to run the cell therapy company, which Gilead snagged in 2017 for $ 12 billion. She’ll… Read More »